BCYC - Bicycle Therapeutics gives out pipeline update shares rise

Bicycle Therapeutics (BCYC) provides pipeline updates on its early and mid-stage cancer trials and announces plans to start recruitment for its first clinical site outside the United States to test its tumor antigen BT8009.The first patient was dosed in an open-label Phase 1/2 clinical trial evaluating BT8009 in patients with advanced solid tumors, in September.The company says BT8009's pharmacokinetic profile is consistent with preclinical predictions based on early clinical data.Bicycle also says that its tumor-targeted immune cell agonist BT7480 is on track for Phase I trial start in H2 2021.Patient enrolment in the Phase IIa portion of the Phase I/IIa trial of its BT1718 treatment sponsored by Cancer Research UK’s Center for Drug Development remains ongoing and is proceeding according to schedule.Bicycle shares up 10% premarket.

For further details see:

Bicycle Therapeutics gives out pipeline update, shares rise